NO132099B - - Google Patents
Download PDFInfo
- Publication number
- NO132099B NO132099B NO16549566A NO16549566A NO132099B NO 132099 B NO132099 B NO 132099B NO 16549566 A NO16549566 A NO 16549566A NO 16549566 A NO16549566 A NO 16549566A NO 132099 B NO132099 B NO 132099B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- pregnadiene
- dione
- diol
- fluoro
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 229910052731 fluorine Chemical group 0.000 claims description 7
- 239000011737 fluorine Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- AVGAIPMGSIOHFZ-UHFFFAOYSA-N dichloromethane;2-propan-2-yloxypropane Chemical compound ClCCl.CC(C)OC(C)C AVGAIPMGSIOHFZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000002168 ethanoic acid esters Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- -1 undecyl anhydride Chemical class 0.000 description 2
- LDJUYMIFFNTKOI-UHFFFAOYSA-N 2,2-dimethylbutanoyl chloride Chemical compound CCC(C)(C)C(Cl)=O LDJUYMIFFNTKOI-UHFFFAOYSA-N 0.000 description 1
- YCURDTPXHPXCKH-UHFFFAOYSA-N 2-ethylbutanoyl 2-ethylbutanoate Chemical compound CCC(CC)C(=O)OC(=O)C(CC)CC YCURDTPXHPXCKH-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
I tysk utlegningsskrift 1.169.444 beskrives fremstillingen av bl.a. A''" '^-l6a-methyl-steroider av formelen: In German explanatory document 1,169,444, the production of, among other things, is described. A''" '^-16a-methyl steroids of the formula:
hvor R og R2er hydrogen eller halogen, og R^er hydrogen eller lavere acyl. where R and R 2 are hydrogen or halogen, and R 2 is hydrogen or lower acyl.
Disse forbindelser har gode betennelseshemmende virkning, idet bivirkninger, som f.eks. påvirkningen av mineralstoffskifte, til tross for den mineralocorticoider nærstående struktur, er over-ordentlig liten. These compounds have good anti-inflammatory effects, since side effects, such as e.g. the influence of mineral metabolism, despite the mineralocorticoids close structure, is extremely small.
For den praktiske anvendelse av kjemiske forbindelser som legemidler er imidlertid ikke bare de ovenfor angitte fordeler be-stemmende. Av spesiell betydning er også virkningsvarigheten og virkningsintensitet (dvs. sammenhengen mellom doseringen på den ene side og tidsforløpet inntil begynnelsen av virkningen respektive inntredelsen av den fulle virkning). For the practical use of chemical compounds as pharmaceuticals, however, not only the advantages stated above are decisive. Also of particular importance is the duration of action and intensity of action (i.e. the relationship between the dosage on the one hand and the time until the onset of the effect or the onset of the full effect).
Ved videreutviklingen av undersøkelsene ifølge DAS I.l69«444 har det nu overraskende vist seg at nettopp 21-acylesterne hvori R^ er en acylgruppe med 7 - 16 carbonatomer i rett kjede eller 4 - 16 carbonatomer i forgrenet kjede, er særlig verdifulle virke-stoffer da de dessuten har en høy virkningsintensitet og en lengre virkningsvarighet. In the further development of the investigations according to DAS I.169«444, it has now surprisingly been shown that precisely the 21-acyl esters in which R^ is an acyl group with 7 - 16 carbon atoms in a straight chain or 4 - 16 carbon atoms in a branched chain, are particularly valuable substances as they also have a high intensity of action and a longer duration of action.
Virkningsintensiteten ble bestemt ved den kjente Vasokonstrik-sjonsprøve på sunne mannlige forsøkspersoner i alderen 18 - 38 år. I tabell 1 er virkningsintensiteten av de ifølge oppfinnelsen frem-stilte 21-estere, f.eks. 21-esterne II og III eksempelvis stillet overfor de kjente forbindelser Ia og Ib til sammenligning, idet t/2 angir tidspunktet ved hvilket der med den respektive forsøksfor-bindelse er oppnådd 50%-ig helbredelse. The intensity of action was determined by the known Vasoconstriction test on healthy male subjects aged 18 - 38 years. In table 1, the intensity of action of the 21-esters produced according to the invention, e.g. The 21-esters II and III, for example, are placed against the known compounds Ia and Ib for comparison, with t/2 indicating the time at which 50% healing has been achieved with the respective test compound.
Tabell 1 viser at de nye 21-estere fremstilt ifølge oppfinnelsen med hensyn til virkningsbegynnelsen og virkningsintensiteten (t/2) er helt overlegne overfor sammenligningsforbindelsene. For de fleste forbindelser oppnåes dette overlegne resultat dessuten med til dels vesentlig lavere dosering. Table 1 shows that the new 21-esters produced according to the invention with regard to the onset of action and the intensity of action (t/2) are completely superior to the comparison compounds. For most compounds, this superior result is also achieved with, in some cases, significantly lower dosages.
Virkningsvarigheten av de nye 21-estere ble bestemt på hann-rotter (80 - 100 g), som på den høyre pote ved intraplantar injeksjon med varmedrepte og frysningstørrede bakterier av stammenMycobacter-ium butyricum (0,05 ml av en0,5%-ig suspensjon i paraffinolje) var påført et ødem. Steroidbehandlingen begynte 2k timer senere. For-søksforbindelsen ble anvendt intramuskulært i form av en ricinusolje-oppløsning. Ødemutviklingen ble fulgt før og efter steroidbehandlingen ved daglige volummålinger. I tabell 2 påvises den overlegne virkningsvarighet av de nye 21-estere ved eksempelvis forbindels-ene 1-9 sammenlignet med de tidligere kjente forbindelser Ia- og Ib-acetat, idet der som endepunkt på virkningsvarigheten ble fast-lagt den dag da der ikke lenger kunne påvises noen forskjell mellom kontroll- og den behandlede dyregruppe (de angitte verdier er middel-verdier idet hver dyregruppe omfatter 7 - IO forsøksdyr). The duration of action of the new 21-esters was determined on male rats (80 - 100 g), which on the right paw by intraplantar injection with heat-killed and freeze-dried bacteria of the strain Mycobacter-ium butyricum (0.05 ml of a 0.5%-ig suspension in paraffin oil) had caused an oedema. Steroid treatment began 2k hours later. The test compound was used intramuscularly in the form of a castor oil solution. Edema development was followed before and after the steroid treatment by daily volume measurements. In table 2, the superior duration of action of the new 21-esters is demonstrated by, for example, compounds 1-9 compared to the previously known compounds Ia- and Ib-acetate, the end point of the duration of action being determined as the day when there is no longer could be demonstrated any difference between the control and the treated animal group (the stated values are mean values as each animal group comprises 7 - 10 experimental animals).
Foreliggende oppfinnelse angar altså analogifremgangsmater ved fremstilling av de tidligere ikke beskrevne 21-estere av A 1 ' L-l6a-methyl-steroider av den generelle formel: The present invention therefore relates to analogous processes for the production of the previously undescribed 21-esters of A 1 ' L-16a-methyl steroids of the general formula:
hvor X er hydrogen eller fluor, og R' er en 7 - 16 carbonatomer inneholdende rettkjedet eller en 4 - 16 carbonatomer inneholdende forgrenet kjede acylgruppe, ved at man a) a) i de tilsvarende frie 21-alkoholer på i og for seg kjent vis forestrer den frie 21-hydroxylgruppe med den ønskede syre, where X is hydrogen or fluorine, and R' is a 7 - 16 carbon atoms containing the straight chain or a 4 - 16 carbon atoms containing branched chain acyl group, by a) a) in the corresponding free 21-alcohols in a manner known per se esterifies the free 21-hydroxyl group with the desired acid,
respektive et reaksjonsdyktig derivat derav, ellerrespectively a reactive derivative thereof, or
b) på i og for seg kjent vis overfører ^^-dobbettbindingen i utgangssteroidene av formelen: b) in a manner known per se, the ^^-doublet bond in the starting steroids transfers the formula:
hvor R" er hydrogen eller R', til lip-0H-9a-fluorgrupperingen, og, hvis i det erholdte primærprodukt R• er hydrogen, selektivt forestrer 21-hydroxylgruppen med den ønskede syre, respektive et reaksjonsdyktig derivat derav. where R" is hydrogen or R', to the lip-OH-9a-fluorine grouping, and, if in the obtained primary product R• is hydrogen, selectively esterifies the 21-hydroxyl group with the desired acid, respectively a reactive derivative thereof.
Den teknisk enkleste fremstillingsmåte a) går ut fra de tilsvarende 21-alkoholer (R* = H) i hvilke på i og for seg kjent vis den frie 21-hydroxylgruppe selektivt forestres med den ønskede syre The technically simplest preparation method a) starts from the corresponding 21-alcohols (R* = H) in which, in a manner known per se, the free 21-hydroxyl group is selectively esterified with the desired acid
respektive et reaksjonsdyktig syrederivat.respectively a reactive acid derivative.
De nye 21-estere hvor X er fluor, kan imidlertid også frem-stilles ifølge oppfinnelsen b) fra 9,11-umettede forbindelser av formelen: However, the new 21-esters where X is fluorine can also be produced according to the invention b) from 9,11-unsaturated compounds of the formula:
hvor R" er hydrogen eller R', idet man på i og for seg kjent måte omdannerA<9>(<H>)-dobbeltbindingen til den til slutt ønskede llp-OH-9a-fluorgruppering og, i det tilfelle at i det erholdte primære produkt R" er hydrogen, forest res 21-hydroxygruppen selektivt med den ønskede syre, respektive et reaksjonsdyktig derivat derav. where R" is hydrogen or R', converting the A<9>(<H>) double bond to the ultimately desired llp-OH-9a-fluorine grouping in a manner known per se and, in the event that in the obtained primary product R" is hydrogen, the 21-hydroxy group is esterified selectively with the desired acid, or a reactive derivative thereof.
Omvandlingen av A^(^^-dobbeltbindingen til den til slutt ønskede ll(3-OH-9a-fluorgruppering skjer fortrinnsvis ved anleiring av underhalogensyre ved 9,11-dobbeltbindingen, f.eks. ved behandling The conversion of the A^(^^-double bond to the ultimately desired 11(3-OH-9a-fluorine grouping preferably takes place by anchoring a hypohalic acid at the 9,11-double bond, e.g. by treatment
med dibromdimethylhydantoin, N-brom-(resp. klor)-acetamid eller N-brom-(resp. klor)-succinimid på vanlig vis. with dibromodimethylhydantoin, N-bromo-(resp. chloro)-acetamide or N-bromo-(resp. chloro)-succinimide in the usual way.
ll(3-0H-9a.-brom-(hhv. klor)-grupperingen overføres på i og for seg kjent vis til 9,11-oxydoringen, som derpå ved hjelp av hydrogen-fluorid omvandles til den til slutt ønskede lip-0H-9a-fluorgrupper-ing . The ll(3-OH-9a.-bromo-(or chlorine) grouping is transferred in a manner known per se to the 9,11-oxydo ring, which is then converted with the help of hydrogen fluoride into the ultimately desired lip-OH -9a-fluorine groups-ing .
De som utgangsmateriale anvendbare A^(<11>)-steroider fåes fraThe A^(<11>) steroids usable as starting material are obtained from
de tilsvarende mettede lip-hydroxylforbindelser. Avspaltningen av lip-hydroxylgruppen skjer ved i og for seg kjente metoder, f.eks. ved behandling med mesylklorid eller også tosylklorid, idet en samtidig-tilstedeværende, fri 21-hydroxylgruppe beskyttes foreløpig. Den fore-løpige 21-hydroxylgruppebeskyttelse utelates når 21-OH-gruppen allerede er forestret den til slutt ønskede syre (R" = R<*>). the corresponding saturated lip-hydroxyl compounds. The cleavage of the lip-hydroxyl group takes place by methods known per se, e.g. by treatment with mesyl chloride or also tosyl chloride, a co-present, free 21-hydroxyl group being temporarily protected. The preliminary 21-hydroxyl group protection is omitted when the 21-OH group is already esterified to the ultimately desired acid (R" = R<*>).
Eksempel 1 Example 1
l6a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion-21-ønanthat 16α-methyl-6α-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione-21-oenanthate
2 g l6a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion får lov til å stå i 8 ml pyridin med 4 ml.ønanthsyreanhydrid ved værelsetemperatur. Det utkrystalliserte ønanthat avsuges og om-kryst alliseres flere ganger fra methylenklorid-isopropylether. Smp. 226 - 227°C. Utbytte 80% av det teoretiske. UV: 2L, 2~1^-2o°-Eksempel 2 l6a-methyl-6a-fluor- A1'^-pregnadien-lip,21-diol-3,20-dion-21-t - butylacetat 1 g l6a-methyl-6a-fluor-A1 ,Zf-pregnadien-lip ,21-diol-3,20-dion omrøres i 25 ml pyridin med 2 ml t-butylacetylklorid i 16 timer ved -7°C. Det opparbeides som i eksempel 12 beskrevet. Efter omkrystallisasjon fra isopropylether-methylenklorid fåes 750 mg l6a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion-21-t-butyl-acetat med smeltepunkt 211 - 213°C. 2 g of 16a-methyl-6a-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione is allowed to stand in 8 ml of pyridine with 4 ml of enoanthic anhydride at room temperature. The crystallized enanthate is filtered off with suction and recrystallized several times from methylene chloride-isopropyl ether. Temp. 226 - 227°C. Yield 80% of the theoretical. UV: 2L, 2~1^-2o°-Example 2 l6a-methyl-6a-fluoro-Al'^-pregnadiene-lip,21-diol-3,20-dione-21-t - butyl acetate 1 g l6a-methyl -6a-fluoro-A1,Zf-pregnadiene-lip,21-diol-3,20-dione is stirred in 25 ml of pyridine with 2 ml of t-butylacetyl chloride for 16 hours at -7°C. It is worked up as described in example 12. After recrystallization from isopropyl ether-methylene chloride, 750 mg of 16a-methyl-6a-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione-21-t-butyl-acetate with melting point 211 - 213 °C.
UV: £2Za= 15.850. UV: £2Za= 15,850.
Eksempel 3 Example 3
l6a-methyl-6a-fluor- A1 '^-pregnadien-lip,21-diol-3,20-dion-21-undecylat 8 g 16a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion får lov til å stå i 60 ml pyridin med 13 g undecylsyreanhydrid i 48 timer ved 20°C. Efter opparbeidelse som i eksempel 8 beskrevet, rives det urene l6a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion-21-undecylat med pentan og omkrystalliseres fra isopropylether. 16a-methyl-6a-fluoro-A1'^-pregnadiene-lip,21-diol-3,20-dione-21-undecylate 8 g 16a-methyl-6a-fluoro-A<1>'^-pregnadiene-lip, 21-diol-3,20-dione is allowed to stand in 60 ml of pyridine with 13 g of undecyl anhydride for 48 hours at 20°C. After working up as described in Example 8, the impure 16a-methyl-6a-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione-21-undecylate is triturated with pentane and recrystallized from isopropyl ether.
Smp. 66 - 67°C. Utbytte 95%.Temp. 66 - 67°C. Yield 95%.
Eks empe1 4Ex empe1 4
l6g- methyl- 6g- fluor- A1 '^- pregnadien- lip, 21- diol- 3, 2Q- dion- 21- palmitat 1 g l6a-methyl-6a-fluor-A<1>'^-pregnadien-llp,21-diol-3,20-dion omrøres i 20 ml pyridin med 1 ml palmitinsyreklorid i 48 timer ved +7°C og opparbeides som beskrevet i eksempel 8. Det således erholdte l6a-methyl-6a-fluor- A1 ,Zf-pregnadien-lip ,21-diol-3 ,20-dion-21-palmitat omkrystalliseres fra isopropylether og smelter ved 93 - 94°C. Utbytte 80%. l6g- methyl- 6g- fluoro- A1 '^- pregnadiene- lip, 21- diol- 3, 2Q- dione- 21- palmitate 1 g l6a-methyl-6a-fluoro- A<1>'^-pregnadiene-llp, 21-diol-3,20-dione is stirred in 20 ml of pyridine with 1 ml of palmitic acid chloride for 48 hours at +7°C and worked up as described in example 8. The 16a-methyl-6a-fluoro-A1,Zf-pregnadiene thus obtained -lip ,21-diol-3,20-dione-21-palmitate is recrystallized from isopropyl ether and melts at 93 - 94°C. Yield 80%.
Eksempel 5Example 5
l6a-methyl-9a-fluor- A<1>'^-pregnadien-lip,21-diol-3,20-dion-21-tri-methylacetat 16α-methyl-9α-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione-21-trimethylacetate
2 g l6a-methyl-9a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion i 20 ml pyridin omsettes med 2,5 ml pivalinsyreklorid og opparbeides som beskrevet i eksempel 8- 2 g of 16a-methyl-9a-fluoro-α<1>'^-pregnadiene-lip,21-diol-3,20-dione in 20 ml of pyridine are reacted with 2.5 ml of pivalic acid chloride and worked up as described in example 8-
Smp. 205,5 - 206,5°C. Utbytte 80% av det teoretiske.Temp. 205.5 - 206.5°C. Yield 80% of the theoretical.
Eksempel 6Example 6
l6a-methyl-6a-fluor- A<1>'^-pregnadien-llp,21-diol-3,20-dion-21-dimethylacetat 16α-methyl-6α-fluoro-α<1>'^-pregnadiene-1β,21-diol-3,20-dione-21-dimethylacetate
1 g l6a-methyl-6a-fluor- A1'^-pregnadien-lip,21-diol-3,20-dion i IO ml pyridin omsettes med 1,2 ml isosmørsyreklorid og opparbeides som beskrevet i eksempel 8> 1 g of 16a-methyl-6a-fluoro-A1'^-pregnadiene-lip,21-diol-3,20-dione in 10 ml of pyridine is reacted with 1.2 ml of isobutyric acid chloride and worked up as described in example 8>
Smp. 187 - 188°C. Utbytte 90% av det teoretiske.Temp. 187 - 188°C. Yield 90% of the theoretical.
UV: £2^2= 15-900. UV: £2^2= 15-900.
Eksempel J Example J
16a-methyl-6a-f luor- A1 '^"-pregnadien-llfB ,21-diol-3 ,20-dion-21 - diethylacetat 16α-methyl-6α-fluoro-α1'^"-pregnadiene-llfB,21-diol-3,20-dione-21-diethylacetate
1 g l6a-methyl-6a-fluor-A1'^-pregnadien-llp,21-diol-3,20-dion 1 g 16a-methyl-6a-fluoro-Al'^-pregnadiene-11p,21-diol-3,20-dione
får lov til å stå i 5 ml pyridin med 2,5 ml diethyleddiksyreanhydrid i 20 timer ved værelsetemperatur og opparbeides som beskrevet i eksempel 8- Efter omkrystallisasjon fra eddiksyreester fåes 780 mg 16a-methyl-6a-f luor- A1 ,if-pregnadien-lip ,21-diol-3 ,20-dion-21-diethyl - acetat med smeltepunkt 230 - 233°C. is allowed to stand in 5 ml of pyridine with 2.5 ml of diethylacetic anhydride for 20 hours at room temperature and is worked up as described in example 8- After recrystallization from acetic acid ester, 780 mg of 16a-methyl-6a-fluoro-A1,if-pregnadiene- lip ,21-diol-3,20-dione-21-diethyl - acetate with melting point 230 - 233°C.
Eksempel 8 Example 8
16a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion-21-tri-methylacetat 2 g 16a-methyl-6a-fluor-A<1>'^-pregnadien-lip,21-diol-3,20-dion omrøres i 20 ml pyridin med 2,5 ml pivalinsyreklorid i 16 timer ved +5°C og helles derpå i isvann. Det avsugede bunnfall tas opp i eddiksyreester, vaskes med 1 n svovelsyre, n/10 natronlut og vann, inndampes og omkrystalliseres fra carbontetraklorid. 16a-methyl-6a-fluoro-A<1>'^-pregnadiene-lip,21-diol-3,20-dione-21-tri-methylacetate 2 g 16a-methyl-6a-fluoro-A<1>'^ -pregnadiene-lip,21-diol-3,20-dione is stirred in 20 ml of pyridine with 2.5 ml of pivalic acid chloride for 16 hours at +5°C and then poured into ice water. The aspirated precipitate is taken up in acetic acid ester, washed with 1 N sulfuric acid, n/10 caustic soda and water, evaporated and recrystallized from carbon tetrachloride.
Smp. 171 - 173°C. Utbytte 90% av det teoretiske. UV: E 2Zf2 =15.600.Temp. 171 - 173°C. Yield 90% of the theoretical. UV: E 2 Zf 2 =15,600.
Eks empel 9Example 9
l6a-methyl-6a-f luor- A1 ,Zf-pregnadien-llp ,21-diol-3,20-dion-21 -2 ' ,2* - dimethylbutyrat 3 g l6a-methyl-6a-f luor-A1 ,Zf-pregnadien-ll|3 ,21-diol-3,20-dion i 75 ml pyridin ved -5°C tilsettes 6 ml 2,2-dimethyl-smørsyreklorid og omrøres i 16 timer ved 4 - 6°C.Opparbeidelsen skjer som beskrevet i eksempel 8. Det således erholdte l6a-methyl-6a-fluor-A1 '^-pregnadien-lip ,21-diol-3,20-dion-21-2" ,2 • -dimethylbutyrat omkrystalliseres fra isopropylether-methylenklorid og smelter ved l6l - 163°C. l6a-methyl-6a-fluor-A1 ,Zf-pregnadiene-llp ,21-diol-3,20-dione-21 -2 ' ,2* - dimethylbutyrate 3 g l6a-methyl-6a-fluor-A1 ,Zf -pregnadiene-ll|3,21-diol-3,20-dione in 75 ml of pyridine at -5°C, 6 ml of 2,2-dimethyl-butyric acid chloride is added and stirred for 16 hours at 4 - 6°C. The preparation takes place as described in example 8. The thus obtained 16α-methyl-6α-fluoro-α1'^-pregnadiene-lip,21-diol-3,20-dione-21-2",2•-dimethylbutyrate is recrystallized from isopropyl ether-methylene chloride and melted at l6l - 163°C.
Utbytte 85% av det teoretiske. UV: E 24l = 1-5-800.Yield 85% of the theoretical. UV: E 24l = 1-5-800.
Eksempel 10 Example 10
6a,9a-difluor-l6a-met hyl-1,4-pregnadien-lip,21-diol-3,20-dion-21-t rimethylacetat 6α,9α-difluoro-16α-methyl-1,4-pregnadiene-lip,21-diol-3,20-dione-21-trimethylacetate
200 mg 6a ,9a-dif luor-l6a-methyl-1,4-pregnadien-ll(3 ,21-diol-3,20-dion oppløses i 2 ml pyridin og tilsettes 0,25 ml trimethyl-eddiksyreklorid. Oppløsningen får lov til å stå i l6 timer ved O - 5°C, omrøres derpå i 2 timer ved værelsetemperatur (ca. 22°C) og helles derpå i isvann. Efter 30 minutters omrøring avsuges de utfelte krystaller og oppløses igjen i vandig eddiksyre. Eddiksyre-esteroppløsningen vaskes med 5%-ig eddiksyre, med vann, med natrium-bicarbonatoppløsning og igjen med vann, tørres over natriumsulfat og konsentreres i vakuum. Det utfelte krystallisat omkrystalliseres fra isopropylether-methylenklorid. Dissolve 200 mg of 6a,9a-difluoro-16a-methyl-1,4-pregnadiene-11(3,21-diol-3,20-dione in 2 ml of pyridine and add 0.25 ml of trimethyl-acetic acid chloride. The solution is allowed to to stand for 16 hours at 0 - 5°C, then stirred for 2 hours at room temperature (approx. 22°C) and then poured into ice water. After 30 minutes of stirring, the precipitated crystals are suctioned off and dissolved again in aqueous acetic acid. the ester solution is washed with 5% acetic acid, with water, with sodium bicarbonate solution and again with water, dried over sodium sulfate and concentrated in vacuo.The precipitated crystallisate is recrystallized from isopropyl ether-methylene chloride.
Utbytte 185 mg. Smp. 218 - 219°C. UV: t239 ~<1>7-200.Yield 185 mg. Temp. 218 - 219°C. UV: t239 ~<1>7-200.
Eksempel 11 Example 11
6a , 9a-dif luor-:16a-methy 1-1,4-pregnadien-llp ,21 -diol-3 ,20-dion-21 - ønanthat 6a , 9a-difluoro-:16a-methyl 1-1,4-pregnadiene-llp ,21 -diol-3 ,20-dione-21 - enanthate
4O0 mg 6a ,9ct-dif luor-l6a-methyl-1,4-pregnadien-ll|3 ,21-diol-3,20-dion oppløses i 1,6 ml pyridin, tilsettes 0,8 ml ønanthsyre-anhydrid og får stå i 24 timer ved værelsetemperatur. Oppløsningen røres i 20 ml 8%-ig svovelsyre av 0°C. Blandingen ekstraheres med methylenklorid. Ekstraktet vaskes med vann, natriumbicarbonatoppløs-ning og igjen med vann, tørres over natriumsulfat og inndampes til tørrhet i vakuum. Det erholdte residuum omkrystalliseres fra aceton-isopropylether. Dissolve 400 mg of 6a,9ct-difluoro-16a-methyl-1,4-pregnadiene-11|3,21-diol-3,20-dione in 1.6 ml of pyridine, add 0.8 ml of enoanthic anhydride and get stand for 24 hours at room temperature. The solution is stirred in 20 ml of 8% sulfuric acid at 0°C. The mixture is extracted with methylene chloride. The extract is washed with water, sodium bicarbonate solution and again with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residue obtained is recrystallized from acetone-isopropyl ether.
Smp. 212 - 213 - 214°C. Utbytte 425 mg. UV:B23y =16.800. Temp. 212 - 213 - 214°C. Yield 425 mg. UV: B23y = 16,800.
Eksempel 12 Example 12
6a ,9a-dif luor-l6a-methyl-1,4-pregnadien-ll|3 ,21-diol-3 ,20-dion-21 - undecylat 6a,9a-difluoro-16a-methyl-1,4-pregnadiene-11|3,21-diol-3,20-dione-21-undecylate
Til en oppløsning av 650mg undecylsyreanhydrid i 3 ml pyridin tilsettes 400 mg 6a ,9a-dif luor-l6a-methyl-l ,4-pregnadien-ll(3 ,21-diol-3,20-dion. Oppløsningen får stå i 48 timer ved værelsetemperatur og tilsettes derpå ca. 5 ml vann og ekstraheres med ether. Eks-trakten vaskes med 2 n svovelsyre, med 2 n natronlut og derpå med vann, tørres og inndampes til tørrhet. Residuet vaskes med pentan og omkrystalliseres fra isopropylether. To a solution of 650 mg of undecyl anhydride in 3 ml of pyridine, 400 mg of 6a,9a-difluoro-16a-methyl-1,4-pregnadiene-11(3,21-diol-3,20-dione is added. The solution is allowed to stand for 48 hours at room temperature and then add approx. 5 ml of water and extract with ether. The extract is washed with 2 N sulfuric acid, with 2 N caustic soda and then with water, dried and evaporated to dryness. The residue is washed with pentane and recrystallized from isopropyl ether.
Smp. 100/101-102°C. Utbytte 369 mg. UV:£336<=>l6-6o°-Temp. 100/101-102°C. Yield 369 mg. UV:£336<=>l6-6o°-
o o
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DESC037995 | 1965-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO132099B true NO132099B (en) | 1975-06-09 |
NO132099C NO132099C (en) | 1975-09-17 |
Family
ID=7434527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO16549566A NO132099C (en) | 1965-11-09 | 1966-11-08 |
Country Status (9)
Country | Link |
---|---|
BR (1) | BR6684410D0 (en) |
CH (1) | CH479566A (en) |
DE (1) | DE1493178C3 (en) |
DK (2) | DK122452B (en) |
ES (1) | ES333171A1 (en) |
FI (1) | FI44908C (en) |
FR (1) | FR6752M (en) |
NL (1) | NL153879B (en) |
NO (1) | NO132099C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2920726A1 (en) * | 1979-05-18 | 1980-11-27 | Schering Ag | NEW CORTICOIDS, THEIR PRODUCTION AND USE |
EP2596007B1 (en) * | 2010-07-20 | 2016-01-06 | Taro Pharmaceutical Industries Ltd | Process for the preparation of 17-desoxy-corticosteroids |
-
1965
- 1965-11-09 DE DE1493178A patent/DE1493178C3/en not_active Expired
-
1966
- 1966-11-08 NL NL666615746A patent/NL153879B/en not_active IP Right Cessation
- 1966-11-08 ES ES0333171A patent/ES333171A1/en not_active Expired
- 1966-11-08 DK DK579266A patent/DK122452B/en unknown
- 1966-11-08 FI FI293166A patent/FI44908C/en active
- 1966-11-08 NO NO16549566A patent/NO132099C/no unknown
- 1966-11-09 CH CH1612866A patent/CH479566A/en not_active IP Right Cessation
- 1966-11-09 BR BR18441066A patent/BR6684410D0/en unknown
- 1966-11-09 FR FR83024A patent/FR6752M/fr not_active Expired
-
1970
- 1970-01-07 DK DK5670A patent/DK122453B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CH479566A (en) | 1969-10-15 |
DE1493178C3 (en) | 1975-05-15 |
NL6615746A (en) | 1967-05-10 |
FR6752M (en) | 1969-03-03 |
FI44908C (en) | 1972-02-10 |
NO132099C (en) | 1975-09-17 |
DK122452B (en) | 1972-03-06 |
DE1493178A1 (en) | 1969-06-04 |
NL153879B (en) | 1977-07-15 |
DE1493178B2 (en) | 1974-08-29 |
FI44908B (en) | 1971-11-01 |
BR6684410D0 (en) | 1973-12-04 |
ES333171A1 (en) | 1967-09-16 |
DK122453B (en) | 1972-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO137321B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3-OXO-17ALFA-ACYLOXYANDROST-4-EN-17BETA-CARBOXYLIC ACID ESTERS | |
DK154145B (en) | METHOD OF PREPARING CORTICOID-17-ALKYL CARBONATE | |
NO157020B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3,20-DIOXO-1,4-PREGNADIENE-17ALFA-OL-17-AROMATIC HETEROCYCLIC CARBOXYLATES. | |
NO148662B (en) | Conditioning shampoos. | |
NO124646B (en) | ||
NO156515B (en) | SKIN PREPARATION. | |
US3170919A (en) | A-nor derivatives of the pregnane series and intermediates in the production thereof | |
NO132099B (en) | ||
NO157864B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY EFFECTIVE DICHLORATED 16ALFA METHYL PREPARATION DERIVATIVES. | |
US2855413A (en) | 16-haloestradiol esters and ethers | |
NO137754B (en) | ANALOGICAL PROCEDURE FOR PREPARING THERAPEUTICALLY ACTIVE STEROID COMPOUNDS | |
NO127190B (en) | ||
Shapiro et al. | Synthesis and progestational activity of some 1, 2. alpha.-cyclomethylene-16-methylene progesterone derivatives | |
US3627757A (en) | 6-alkanoylthio-4-en-3-oxo steroids and process for production thereof | |
FI62317B (en) | FRAMEWORK FOR THE PHARMACOLOGICAL PROPERTIES OF DIFFERENT D-HOMOSTEROIDER | |
US4116978A (en) | D-homo oxasteroids | |
NO125050B (en) | ||
NO132391B (en) | ||
NO119469B (en) | ||
US3025312A (en) | 9alpha, 11beta-dichloro pregnanes | |
US3261831A (en) | 11-keto-12beta-hydroxy progesterone and derivatives thereof | |
US3009932A (en) | 6-fluoro-9alpha, 11beta- 21-trihalo-progesterones | |
CA1040191A (en) | Corticold hormones | |
US2901397A (en) | 11-oxygenated 9alpha-21-difluoro-1,4 pregnadiene steroidal compositions | |
US3082219A (en) | Method for the preparation of delta16-20-keto steroids |